Endogenous Fe

Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could resp...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Chen, Jufeng [verfasserIn] Xue, Fengfeng [verfasserIn] Du, Wenxian [verfasserIn] Deng, Xi [verfasserIn] Wu, Yiji [verfasserIn] Chen, Hangrong [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2023

Schlagwörter:	Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin

Übergeordnetes Werk:	Enthalten in: The chemical engineering journal - Amsterdam : Elsevier, 1997, 471
Übergeordnetes Werk:	volume:471

DOI / URN:	10.1016/j.cej.2023.144358

Katalog-ID:	ELV061360791

Internformat


LEADER	01000caa a22002652 4500
001	ELV061360791
003	DE-627
005	20231208093236.0
007	cr uuu---uuuuu
008	230808s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.cej.2023.144358 \|2 doi
035			\|a (DE-627)ELV061360791
035			\|a (ELSEVIER)S1385-8947(23)03089-9
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
082	0	4	\|a 660 \|q VZ
082	0	4	\|a 660 \|q VZ
084			\|a 58.10 \|2 bkl
100	1		\|a Chen, Jufeng \|e verfasserin \|4 aut
245	1	0	\|a Endogenous Fe
264		1	\|c 2023
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.
650		4	\|a Chemodynamic therapy
650		4	\|a Photothermal therapy
650		4	\|a Ferroptosis
650		4	\|a Copper Prussian blue analogues
650		4	\|a Erastin
700	1		\|a Xue, Fengfeng \|e verfasserin \|4 aut
700	1		\|a Du, Wenxian \|e verfasserin \|4 aut
700	1		\|a Deng, Xi \|e verfasserin \|4 aut
700	1		\|a Wu, Yiji \|e verfasserin \|4 aut
700	1		\|a Chen, Hangrong \|e verfasserin \|0 (orcid)0000-0003-0451-0406 \|4 aut
773	0	8	\|i Enthalten in \|t The chemical engineering journal \|d Amsterdam : Elsevier, 1997 \|g 471 \|h Online-Ressource \|w (DE-627)320500322 \|w (DE-600)2012137-4 \|w (DE-576)098330152 \|x 1873-3212 \|7 nnns
773	1	8	\|g volume:471
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 58.10 \|j Verfahrenstechnik: Allgemeines \|q VZ
951			\|a AR
952			\|d 471

Indexfelder

author_variant	j c jc f x fx w d wd x d xd y w yw h c hc
matchkey_str	article:18733212:2023----::noeo
hierarchy_sort_str	2023
bklnumber	58.10
publishDate	2023
allfields	10.1016/j.cej.2023.144358 doi (DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9 DE-627 ger DE-627 rda eng 660 VZ 660 VZ 58.10 bkl Chen, Jufeng verfasserin aut Endogenous Fe 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy. Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin Xue, Fengfeng verfasserin aut Du, Wenxian verfasserin aut Deng, Xi verfasserin aut Wu, Yiji verfasserin aut Chen, Hangrong verfasserin (orcid)0000-0003-0451-0406 aut Enthalten in The chemical engineering journal Amsterdam : Elsevier, 1997 471 Online-Ressource (DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152 1873-3212 nnns volume:471 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 58.10 Verfahrenstechnik: Allgemeines VZ AR 471
spelling	10.1016/j.cej.2023.144358 doi (DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9 DE-627 ger DE-627 rda eng 660 VZ 660 VZ 58.10 bkl Chen, Jufeng verfasserin aut Endogenous Fe 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy. Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin Xue, Fengfeng verfasserin aut Du, Wenxian verfasserin aut Deng, Xi verfasserin aut Wu, Yiji verfasserin aut Chen, Hangrong verfasserin (orcid)0000-0003-0451-0406 aut Enthalten in The chemical engineering journal Amsterdam : Elsevier, 1997 471 Online-Ressource (DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152 1873-3212 nnns volume:471 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 58.10 Verfahrenstechnik: Allgemeines VZ AR 471
allfields_unstemmed	10.1016/j.cej.2023.144358 doi (DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9 DE-627 ger DE-627 rda eng 660 VZ 660 VZ 58.10 bkl Chen, Jufeng verfasserin aut Endogenous Fe 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy. Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin Xue, Fengfeng verfasserin aut Du, Wenxian verfasserin aut Deng, Xi verfasserin aut Wu, Yiji verfasserin aut Chen, Hangrong verfasserin (orcid)0000-0003-0451-0406 aut Enthalten in The chemical engineering journal Amsterdam : Elsevier, 1997 471 Online-Ressource (DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152 1873-3212 nnns volume:471 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 58.10 Verfahrenstechnik: Allgemeines VZ AR 471
allfieldsGer	10.1016/j.cej.2023.144358 doi (DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9 DE-627 ger DE-627 rda eng 660 VZ 660 VZ 58.10 bkl Chen, Jufeng verfasserin aut Endogenous Fe 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy. Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin Xue, Fengfeng verfasserin aut Du, Wenxian verfasserin aut Deng, Xi verfasserin aut Wu, Yiji verfasserin aut Chen, Hangrong verfasserin (orcid)0000-0003-0451-0406 aut Enthalten in The chemical engineering journal Amsterdam : Elsevier, 1997 471 Online-Ressource (DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152 1873-3212 nnns volume:471 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 58.10 Verfahrenstechnik: Allgemeines VZ AR 471
allfieldsSound	10.1016/j.cej.2023.144358 doi (DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9 DE-627 ger DE-627 rda eng 660 VZ 660 VZ 58.10 bkl Chen, Jufeng verfasserin aut Endogenous Fe 2023 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy. Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin Xue, Fengfeng verfasserin aut Du, Wenxian verfasserin aut Deng, Xi verfasserin aut Wu, Yiji verfasserin aut Chen, Hangrong verfasserin (orcid)0000-0003-0451-0406 aut Enthalten in The chemical engineering journal Amsterdam : Elsevier, 1997 471 Online-Ressource (DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152 1873-3212 nnns volume:471 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 58.10 Verfahrenstechnik: Allgemeines VZ AR 471
language	English
source	Enthalten in The chemical engineering journal 471 volume:471
sourceStr	Enthalten in The chemical engineering journal 471 volume:471
format_phy_str_mv	Article
bklname	Verfahrenstechnik: Allgemeines
institution	findex.gbv.de
topic_facet	Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin
dewey-raw	660
isfreeaccess_bool	false
container_title	The chemical engineering journal
authorswithroles_txt_mv	Chen, Jufeng @@aut@@ Xue, Fengfeng @@aut@@ Du, Wenxian @@aut@@ Deng, Xi @@aut@@ Wu, Yiji @@aut@@ Chen, Hangrong @@aut@@
publishDateDaySort_date	2023-01-01T00:00:00Z
hierarchy_top_id	320500322
dewey-sort	3660
id	ELV061360791
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV061360791</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231208093236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230808s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cej.2023.144358</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV061360791</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1385-8947(23)03089-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chen, Jufeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endogenous Fe</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemodynamic therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photothermal therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ferroptosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Copper Prussian blue analogues</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Erastin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Fengfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Du, Wenxian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deng, Xi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Yiji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Hangrong</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-0451-0406</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The chemical engineering journal</subfield><subfield code="d">Amsterdam : Elsevier, 1997</subfield><subfield code="g">471</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)320500322</subfield><subfield code="w">(DE-600)2012137-4</subfield><subfield code="w">(DE-576)098330152</subfield><subfield code="x">1873-3212</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:471</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">471</subfield></datafield></record></collection>
author	Chen, Jufeng
spellingShingle	Chen, Jufeng ddc 660 bkl 58.10 misc Chemodynamic therapy misc Photothermal therapy misc Ferroptosis misc Copper Prussian blue analogues misc Erastin Endogenous Fe
authorStr	Chen, Jufeng
ppnlink_with_tag_str_mv	@@773@@(DE-627)320500322
format	electronic Article
dewey-ones	660 - Chemical engineering
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
issn	1873-3212
topic_title	660 VZ 58.10 bkl Endogenous Fe Chemodynamic therapy Photothermal therapy Ferroptosis Copper Prussian blue analogues Erastin
topic	ddc 660 bkl 58.10 misc Chemodynamic therapy misc Photothermal therapy misc Ferroptosis misc Copper Prussian blue analogues misc Erastin
topic_unstemmed	ddc 660 bkl 58.10 misc Chemodynamic therapy misc Photothermal therapy misc Ferroptosis misc Copper Prussian blue analogues misc Erastin
topic_browse	ddc 660 bkl 58.10 misc Chemodynamic therapy misc Photothermal therapy misc Ferroptosis misc Copper Prussian blue analogues misc Erastin
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	The chemical engineering journal
hierarchy_parent_id	320500322
dewey-tens	660 - Chemical engineering
hierarchy_top_title	The chemical engineering journal
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)320500322 (DE-600)2012137-4 (DE-576)098330152
title	Endogenous Fe
ctrlnum	(DE-627)ELV061360791 (ELSEVIER)S1385-8947(23)03089-9
title_full	Endogenous Fe
author_sort	Chen, Jufeng
journal	The chemical engineering journal
journalStr	The chemical engineering journal
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2023
contenttype_str_mv	zzz
author_browse	Chen, Jufeng Xue, Fengfeng Du, Wenxian Deng, Xi Wu, Yiji Chen, Hangrong
container_volume	471
class	660 VZ 58.10 bkl
format_se	Elektronische Aufsätze
author-letter	Chen, Jufeng
doi_str_mv	10.1016/j.cej.2023.144358
normlink	(ORCID)0000-0003-0451-0406
normlink_prefix_str_mv	(orcid)0000-0003-0451-0406
dewey-full	660
author2-role	verfasserin
title_sort	endogenous fe
title_auth	Endogenous Fe
abstract	Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.
abstractGer	Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.
abstract_unstemmed	Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700
title_short	Endogenous Fe
remote_bool	true
author2	Xue, Fengfeng Du, Wenxian Deng, Xi Wu, Yiji Chen, Hangrong
author2Str	Xue, Fengfeng Du, Wenxian Deng, Xi Wu, Yiji Chen, Hangrong
ppnlink	320500322
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1016/j.cej.2023.144358
up_date	2024-07-06T17:32:59.894Z
_version_	1803851849946628096
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV061360791</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20231208093236.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230808s2023 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.cej.2023.144358</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV061360791</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1385-8947(23)03089-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">58.10</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chen, Jufeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Endogenous Fe</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Endogenous activated nanomedicines have great potential in improving therapeutic efficacy and minimizing side effects in cancer therapy. Herein, a novel nanomedicine (CuHCF) was developed based on a mixed-metal (Cu2+/Fe3+) Prussian blue analogue via a facile co-precipitation method, which could respond to the endogenous labile iron pool (LIP) achieving enhanced chemodynamic therapy (CDT) and in situ NIR-II photothermal therapy (PTT) of tumor. Notably, the prepared CuHCF itself shows low Fenton catalytic activity, which however, is found to significantly amplify the generation of reactive oxidative species (ROS) when exposed to the over-expressed Fe2+ in tumor region, since the intracellular Fe2+ triggers the redox cycles between Fe3+/Fe2+ and Cu2+/Cu+ of CuHCF. More interestingly, it is found that the CuHCF presents an obviously enhanced near-infrared absorption after reacting with Fe2+, enabling in situ hyperthermia under NIR-II (1064 nm) irradiation. Both in vitro and in vivo results demonstrated that a highly efficient synergistic therapy of CDT/PTT was achieved via a ferroptosis pathway when CuHCF was combined with the ferroptosis inducer erastin (ERA). Such an endogenous activated nanomedicine provides a promising paradigm to enhance specific CDT in synergy with in situ NIR-II PTT for precise cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemodynamic therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Photothermal therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ferroptosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Copper Prussian blue analogues</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Erastin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Fengfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Du, Wenxian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Deng, Xi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Yiji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chen, Hangrong</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0003-0451-0406</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The chemical engineering journal</subfield><subfield code="d">Amsterdam : Elsevier, 1997</subfield><subfield code="g">471</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)320500322</subfield><subfield code="w">(DE-600)2012137-4</subfield><subfield code="w">(DE-576)098330152</subfield><subfield code="x">1873-3212</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:471</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">58.10</subfield><subfield code="j">Verfahrenstechnik: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">471</subfield></datafield></record></collection>
score	7.400585

Nicht das Richtige dabei?

Schreiben Sie uns!

Endogenous Fe

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?